[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622850":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":7,"responsibleParty":23,"collaborators":27,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":41,"sex":42,"minAge":7,"maxAge":7,"enrollmentInfo":43,"targetDuration":46,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":58,"overallStatus":62,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":7},{"fullName":5,"class":6},"Gardiens de Vies","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","MAGIA H3S","MagiA H3S : Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis",[14],{"name":15,"affiliation":5,"role":16},"KANA LINGAMBU, MPH","STUDY_CHAIR",[18],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"MAINDO ALONGO, PhD","CONTACT","+243 815 188 470","mike.maindo@gardiensdevies.org",{"type":24,"investigatorFullName":25,"investigatorTitle":26,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","MAINDO ALONGO","Principal Investigator",[28,31],{"name":29,"class":30},"Institut Pasteur","INDUSTRY",{"name":32,"class":30},"MagIA Diagnostics","100622850","magia-h3s-point-of-care-test-performance-for-hiv-hbv-hcv-and-syphilis-screening-in-pregnant-women-in-dr-congo-100622850",false,"NCT07388979","MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo","MAGIa In-vitro- Diagnostics Medical Device Dedicated to Combined Screening of HIV, HBV, HCV and Syphilis and HBV Reflective Panels aMong Congolese pregnAnt woMen Attending to Ante Natal Care Consultations","MAGICS MAM","Inclusion Criteria:\n\n* Being pregnant, regardless of age or stage of pregnancy (prenatal period);\n* Having signed an informed consent form at the start of prenatal care (CPN) to participate in the study.\n\nNote: for pregnant minors, the consent of a parent or legal guardian is required;\n\n* Have chosen to attend prenatal care at the healthcare facility selected for the study;\n* Plan to give birth at the same healthcare facility where they were included in the study;\n* Plan to attend postnatal care (PNC) and preschool consultations (PSC) at the same healthcare facility where they were included in the study.\n* Plan to give birth at the same health facility where they were enrolled;\n* Plan to attend postnatal consultations (PNC) and preschool consultations (PSC) at the same facility\n\nExclusion Criteria:\n\n* Women in labor or who refuse to give their consent.",true,"FEMALE",{"count":44,"type":45},7500,"ESTIMATED","12 Months","OBSERVATIONAL","Performance study to evaluate the clinical performance of the In-Vitro Diagnostic Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from pregnant women attending antenatal care (ANC) services in the Democratic Republic of the Congo. This study aligns with the WHO 2022-2030 strategy for the integrated elimination of mother-to-child transmission of HIV, HBV, HCV, and syphilis.",[50,51,52,53,54,55,56,57],"HIV - Human Immunodeficiency Virus","HBV (Hepatitis B Virus)","Hepatitis C Virus (HCV)","Syphilis","Mother-to-Child Transmission","Performance","Point of Care STI Testing","TREAT B",[59,60,61],"Triple elimination","Mother-to-child transmission","Democratic republic of the Congo","NOT_YET_RECRUITING","2026-01-28",{"date":65,"type":66},"2026-02-05","ACTUAL",{"date":68,"type":45},"2026-03-01",{"date":70,"type":45},"2027-12-21",{"name":5,"class":6}]